Publication

Circulating Progenitor Cells Identify Peripheral Arterial Disease in Patients With Coronary Artery Disease

Downloadable Content

Persistent URL
Last modified
  • 03/03/2025
Type of Material
Authors
    Salim S. Hayek, Emory UniversityJames MacNamara, Emory UniversityAyman Tahhan, Emory UniversityMosaab Awad, Emory UniversityAdithya Yadalam, Emory UniversityYi-An Ko, Emory UniversitySean Healy, Emory UniversityIraj Hesaroieh, Emory UniversityHina Ahmed, Emory UniversityBrandon Gray, Emory UniversitySalman Sher, Emory UniversityNima Ghasemzadeh, Emory UniversityRiyaz Patel, Emory UniversityJinhee Kim, Emory UniversityEdmund Waller, Emory UniversityArshed Quyyumi, Emory University
Language
  • English
Date
  • 2016-08-05
Publisher
  • American Heart Association
Publication Version
Copyright Statement
  • © 2016 American Heart Association, Inc.
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 0009-7330
Volume
  • 119
Issue
  • 4
Start Page
  • 564
End Page
  • 571
Grant/Funding Information
  • AAQ is supported by 5P01HL101398-02, 1P20HL113451-01, 1R56HL126558-01, 1RF1AG051633-01, R01 NS064162-01, R01 HL89650-01, HL095479-01, 1U10HL110302-01, 1DP3DK094346-01, 2P01HL086773-06A1.
  • SSH is supported by the Abraham J. & Phyllis Katz Foundation (Atlanta, GA).
Supplemental Material (URL)
Abstract
  • Rationale: Peripheral arterial disease (PAD) is a clinical manifestation of extracoronary atherosclerosis. Despite sharing the same risk factors, only 20% to 30% of patients with coronary artery disease (CAD) develop PAD. Decline in the number of bone marrow-derived circulating progenitor cells (PCs) is thought to contribute to the pathogenesis of atherosclerosis. Whether specific changes in PCs differentiate patients with both PAD and CAD from those with CAD alone is unknown. Objective: Determine whether differences exist in PCs counts of CAD patients with and without known PAD. Methods and Results: 1497 patients (mean age: 65 years; 62% men) with known CAD were identified in the Emory Cardiovascular Biobank. Presence of PAD (n=308) was determined by history, review of medical records, or imaging and was classified as carotid (53%), lower extremity (41%), upper extremity (3%), and aortic disease (33%). Circulating PCs were enumerated by flow cytometry. Patients with CAD and PAD had significantly lower PC counts compared with those with only CAD. In multivariable analysis, a 50% decrease in cluster of differentiation 34 (CD34+) or CD34+/vascular endothelial growth factor receptor-2 (VEGFR2+) counts was associated with a 31% (P=0.032) and 183% (P=0.002) increase in the odds of having PAD, respectively. CD34+ and CD34+/VEGFR2+ counts significantly improved risk prediction metrics for prevalent PAD. Low CD34+/VEGFR2+ counts were associated with a 1.40-fold (95% confidence interval, 1.03-1.91) and a 1.64-fold (95% confidence interval, 1.07-2.50) increases in the risk of mortality and PAD-related events, respectively. Conclusions: PAD is associated with low CD34+ and CD34+/VEGFR2+ PC counts. Whether low PC counts are useful in screening for PAD needs to be investigated.
Author Notes
  • Address correspondence to: Dr. Arshed A. Quyyumi, Division of Cardiology, Department of Medicine, Emory University School of Medicine, 1462 Clifton Rd. NE, Suite 507, Atlanta, GA 30322, Tel: (404) 727-3655, Fax: (404) 712-8785, aquyyum@emory.edu
Keywords
Research Categories
  • Health Sciences, Oncology
  • Biology, Biostatistics
  • Biology, Bioinformatics

Tools

Relations

In Collection:

Items